Promosyon programı IMV Inc.
Gelişmiş program
Basit grafik
Seviye
Hafife alma
| İsim |
Anlam |
Seviye |
| P/S |
0 |
0 |
| P/BV |
0 |
0 |
| P/E |
0 |
0 |
Yeterlik
| İsim |
Anlam |
Seviye |
| ROA |
0 |
0 |
| ROE |
0 |
0 |
| ROIC |
0 |
0 |
Temettüler
| İsim |
Anlam |
Seviye |
| Temettü getirisi |
0 |
0 |
| DSI |
0 |
0 |
| Ortalama temettü büyümesi |
0 |
0 |
Görev
| İsim |
Anlam |
Seviye |
| Debt/EBITDA |
0 |
10 |
| Debt/Ratio |
0 |
10 |
| Debt/Equity |
0 |
10 |
Büyüme dürtüsü
| İsim |
Anlam |
Seviye |
| Hasılat, % |
0 |
0 |
| Ebitda, % |
154.97 |
10 |
| EPS, % |
873.03 |
10 |
paper.price.prices
|
Fiyat |
Common.min. |
Common.max. |
Değiştirmek |
paper.changes_in_industry |
paper.changes_in_index |
| common.calendar.number_days.1 |
0.0001 $ |
0 $ |
0 $ |
0 % |
0 % |
0 % |
| common.calendar.number_days.7d |
0.0001 $ |
0 $ |
0 $ |
0 % |
0 % |
0 % |
| common.calendar.number_days.30d |
0.0001 $ |
0 $ |
0 $ |
0 % |
0 % |
0 % |
| common.calendar.number_days.90d |
0.0001 $ |
0.0001 $ |
0.0001 $ |
0 % |
0 % |
0 % |
| common.calendar.number_days.180d |
0.0001 $ |
0.0001 $ |
0.0001 $ |
0 % |
0 % |
0 % |
| common.calendar.number_days.1y |
0.0001 $ |
0.0001 $ |
0.0001 $ |
0 % |
0 % |
0 % |
| common.calendar.number_days.3y |
6.9 $ |
0.0001 $ |
75 $ |
-100 % |
0 % |
0 % |
| common.calendar.number_days.5y |
50.7 $ |
0.0001 $ |
75 $ |
-100 % |
0 % |
0 % |
| common.calendar.number_days.10y |
0.0001 $ |
0.0001 $ |
75 $ |
+100 % |
0 % |
0 % |
| common.calendar.number_days.ytd |
0.0001 $ |
0.0001 $ |
0.0001 $ |
0 % |
0 % |
0 % |
Benzer şirketler
P/E & P/BVEV/Ebitda & Debt/Ebitda
Şirket yönetimi
| Süpervizör |
İş unvanı |
Ödeme |
Doğum yılı |
| Mr. Andrew Hall M.Sc. |
CEO & Director |
680.6k |
|
| Ms. Brittany Davison C.A., CPA |
Chief Accounting Officer, Corporate Secretary & Director |
207.9k |
1990 (35 yıllar) |
| Delphine Davan |
Senior Director of Communications & Investor Relations |
N/A |
|
| Mr. Stephan Fiset M.B.A., M.Sc. |
Vice President of Clinical Research |
N/A |
|
| Dr. Jeremy R. Graff Ph.D. |
Chief Scientific Officer |
|
1971 (54 yıl) |
Şirket hakkında IMV Inc.
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
MAX Sohbet
